Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by Farallon Capital Management LLC

Farallon Capital Management LLC lifted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 79.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,316,227 shares of the medical equipment provider's stock after acquiring an additional 2,361,000 shares during the quarter. Lantheus comprises approximately 2.4% of Farallon Capital Management LLC's holdings, making the stock its 12th biggest holding. Farallon Capital Management LLC owned approximately 7.65% of Lantheus worth $475,590,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after acquiring an additional 435,445 shares in the last quarter. Reinhart Partners LLC. increased its stake in Lantheus by 9.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock worth $122,280,000 after buying an additional 123,282 shares during the period. Dimensional Fund Advisors LP increased its stake in Lantheus by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after buying an additional 30,891 shares during the period. Swedbank AB increased its stake in Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after buying an additional 385,000 shares during the period. Finally, Northern Trust Corp increased its stake in Lantheus by 11.7% during the 4th quarter. Northern Trust Corp now owns 916,384 shares of the medical equipment provider's stock worth $81,980,000 after buying an additional 96,275 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Down 2.7%

Shares of LNTH traded down $2.22 during midday trading on Monday, hitting $79.52. The company had a trading volume of 2,167,057 shares, compared to its average volume of 973,734. The company's 50 day moving average price is $99.15 and its 200 day moving average price is $93.92. The stock has a market cap of $5.45 billion, a price-to-earnings ratio of 13.23 and a beta of 0.23. Lantheus Holdings, Inc. has a 52 week low of $75.00 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same period in the previous year, the firm posted $1.69 EPS. Lantheus's revenue for the quarter was up .8% on a year-over-year basis. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on LNTH shares. JMP Securities reaffirmed a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial dropped their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday. StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday. Finally, B. Riley dropped their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $132.67.

Insider Activity

In other news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. The trade was a 10.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 63,109 shares of company stock valued at $6,016,046. Company insiders own 1.50% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.